GoKawiilResearchers detail TRI-611, a brain-penetrant ALK degrader that boosts TKI efficacy
Preclinical data show TRI-611 forms a ternary complex with ALK kinase and CRBN/DDB1, promoting degradation of ALK protein including the EML4-ALK fusion. Combined with TKIs like alectinib and lorlatinib, TRI-611 enhanced tumor suppression in NCI-H3122 xenograft mice without significant body weight loss, indicating a tolerable combination therapy approach.
GoKawiil's interpretation of the reporting above, not reported fact.
ALK-driven cancers, particularly non-small cell lung cancer, often develop resistance to existing TKIs, and brain metastases remain a major treatment challenge. A brain-penetrant degrader that synergizes with current inhibitors could offer a new strategy to overcome resistance and improve outcomes for patients with ALK-positive tumors.
- TRI-611 induces ALK degradation via CRBN/DDB1 ternary complex formation
- Combination with alectinib or lorlatinib showed synergistic anti-tumor effects in mouse models
- The compound's brain penetration and tolerability support its potential for treating ALK-driven cancers with CNS involvement
Source: nature.com — Conery, 2026-09-09
Published there as: “TRI-611, a selective, brain-penetrant molecular glue degrader of ALK”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.